Skip to main content

Table 1 Patient characteristics

From: A comparative study of transperineal software-assisted magnetic resonance/ultrasound fusion biopsy and transrectal cognitive fusion biopsy of the prostate

  Transperineal biopsy (N = 92) Transrectal biopsy (N = 85) p
Total number of targets 104 92  
Age 66 (61–72) 67 (62–73) 0.61
DRE, n (%)    0.312
 Negative 65 (70.6%) 62 (72.9%)  
 Positive 27 (29.3%) 23 (27.0%)  
Previous biopsy, n (%)    0.844
 Biopsy naïve 64 (69.5%) 57 (67.0%)  
 Repeat biopsy 28 (30.4%) 28 (32.9%)  
PSA, ng/mL 7.5 (5.30–13.28) 8.04 (5.76–12.12) 0.608
Prostate volume, ml 42.34 (29.93–59.08) 43.4 (30.9–54.9) 0.582
PSAD 0.18 (0.11–0.32) 0.18 (0.12–0.27) 0.729
PI-RAS score, n (%)    0.277
 3 19 (18.2%) 13 (14.1%)  
 4 48 (46.1%) 53 (57.6%)  
 5 37 (35.5%) 26 (28.2%)  
Total core number, n 26 (23–28) 20 (16–22) < 0.001
 Targeted biopsy 6 (4–7) 4 (3–4) < 0.001
 Systematic biopsy 19 (17–22) 16 (12–18) < 0.001
Target lesion size, mm 12 (9–19.25) 10.5 (6.75–16) 0.305
Target lesion location, n (%)    
 Anterior 41 (39.4%) 31 (33.6%) 0.406
 posterior 63 (60.5%) 61 (66.3%)  
  1. Continuous data were show as median (IQR)
  2. DRE, digital rectal exam; IQR, interquadrant range; PSA, prostate specific antigen; PSAD, prostate specific antigen density; PI-RADS, Prostate Imaging Reporting & Data System